
Opinion|Videos|September 6, 2024
Pharmacy and Provider Collaboration
Author(s)Sophia Humphreys, PharmD, MHA
Dr Humphreys discusses pharmacy and provider collaboration.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- How can pharmacy teams better collaborate with providers to support the switch to biosimilars, and what strategies can be used to educate both providers and the pharmacy team? What practices have you seen be successful?
Advertisement
Related to this article

The randomized ALLIANCE A051701 trial closed early when treatment-related toxicity and mortality were increased without improving PFS in patients with newly diagnosed double-hit lymphoma.

Artificial intelligence (AI) transforms a chaotic, reactive process into an adaptive, proactive system that improves workflow and patient safety.

New European Respiratory Society (ERS) update makes sotatercept a strong add-on recommendation, opening a fourth pathway for pharmacists to manage.

Robin Tumlinson, PharmD, BCOP, discusses how rapidly expanding bladder cancer options are creating new questions around treatment sequencing, toxicity management, biomarker testing, and multidisciplinary care.

With changes in Medicaid eligibility looming, hospitals must plan now to keep patient care gaps at bay.

Pharmacists are well equipped to manage DOAC therapy by providing initial education, adherence support, and safety monitoring.
Advertisement
Advertisement
Trending on Pharmacy Times
1
How Pharmacists Overcome PCSK9 Inhibitor Access Barriers
2
From Reactive to Proactive: AI's Role in Modern Pharmacy Safety
3
Trial Ended Early When Venetoclax Plus DA-EPOCH-R Did Not Improve Outcomes in Double-Hit Lymphoma
4
Pharmacists' Role as Ketone Monitoring Reaches Clinics
5


